Gennemsnitsvarigheden af forsøgsbehandlingen var væsentligt længere (44, 0 uger) hos lenalidomid/ dexamethason- gruppen end hos placebo/ dexamethason- gruppen (23, 1 uger).
The median duration of exposure to study treatment was significantly longer (44.0 weeks) in the lenalidomide/dexamethasone group as compared to placebo/dexamethasone (23.1 weeks).